Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Defective nucleoli linked to Parkinson's disease

Defective nucleoli linked to Parkinson's disease

Vanderbilt researchers announce multi-national collaboration on Alzheimer's disease genetics

Vanderbilt researchers announce multi-national collaboration on Alzheimer's disease genetics

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Software can predict future of sports concussion: New research

Software can predict future of sports concussion: New research

Global consortium aims to discover and map all Alzheimer's genes

Global consortium aims to discover and map all Alzheimer's genes

Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease

Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

AVANIR's NUEDEXTA for pseudobulbar affect now available by prescription

New research finding shows strong relationship between gut bacteria and fatty liver

New research finding shows strong relationship between gut bacteria and fatty liver

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

Scientists convert adult skin cells into cardiomyocytes using direct reprogramming strategy

Scientists convert adult skin cells into cardiomyocytes using direct reprogramming strategy

HPN President announces gift to UCLA to advance research for Neural Regeneration

HPN President announces gift to UCLA to advance research for Neural Regeneration

Adeona to sell 2.85 million common stock at $1.40 per share

Adeona to sell 2.85 million common stock at $1.40 per share

CIHR announces $8.6 million for new research on Alzheimer's disease

CIHR announces $8.6 million for new research on Alzheimer's disease

Research provides new clues for compulsive behavior, cognitive defects linked with LND

Research provides new clues for compulsive behavior, cognitive defects linked with LND

Neuralstem ends litigation with ReNeuron

Neuralstem ends litigation with ReNeuron

Connectome remains dynamic during development, says Scripps Research

Connectome remains dynamic during development, says Scripps Research

Misaligned research, medical challenges and harsh economics thwart efforts against Alzheimer's disease

Misaligned research, medical challenges and harsh economics thwart efforts against Alzheimer's disease

ALS Biopharma receives ADDF grant to develop therapeutics against Alzheimer's disease

ALS Biopharma receives ADDF grant to develop therapeutics against Alzheimer's disease

New molecular player responsible for regulation of appetite and metabolism

New molecular player responsible for regulation of appetite and metabolism

Study aims to determine risk of dementia, cognitive decline in middle-aged people

Study aims to determine risk of dementia, cognitive decline in middle-aged people

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.